Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 19/20 | 1.00 |
| ▸ | CCNH | P51946 | 19/20 | 1.00 |
| ▸ | CCNK | O75909 | 18/20 | 1.00 |
| ▸ | CDK12 | Q9NYV4 | 17/20 | 1.00 |
| ▸ | CDK9 | P50750 | 16/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 15/20 | 1.00 |
| ▸ | CDK13 | Q14004 | 14/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 14/20 | 1.00 |
| ▸ | CDK2 | P24941 | 14/20 | 1.00 |
| ▸ | MNAT1 | P51948 | 11/20 | 1.00 |
| ▸ | CDK3 | Q00526 | 1/20 | 1.00 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16664894 | 1.00 | CDK7 (1.00) | CDK7CCNHCCNKCDK12CDK9 | |
| SCHEMBL29392974 | 1.00 | CDK7 (1.00) | CDK7CCNHCCNKCDK12CDK9 | |
| SCHEMBL16655251 | 1.00 | CDK7 (1.00) | CDK7CCNHCCNKCDK12CDK9 | |
| SCHEMBL16655248 | 1.00 | CDK7 (1.00) | CDK7CCNHCCNKCDK12CDK9 | |
| SCHEMBL16655250 | 1.00 | CDK7 (1.00) | CDK7CCNHCCNKCDK12CDK9 | |
| SCHEMBL16655252 | 1.00 | CDK7 (1.00) | CDK7CCNHCCNKCDK12CDK9 | |
| SCHEMBL16655070 | 0.97 | CCNK (1.00) | CDK7CCNHCCNKCDK12CDK9 | |
| SCHEMBL16655118 | 0.97 | CCNK (1.00) | CDK7CCNHCCNKCDK12CDK9 | |
| SCHEMBL16655115 | 0.97 | CCNK (1.00) | CDK7CCNHCCNKCDK12CDK9 | |
| SCHEMBL16655072 | 0.97 | CCNK (1.00) | CDK7CCNHCCNKCDK12CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-12351571-B2 | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases | ARRAY BIOPHARMA INC. (US) | 2025-07-08 | — | — | US | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20220081438-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | ARRAY BIOPHARMA INC. | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220081438-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | FGFR1, FGFR4, FGFR3 | CDK7 228/4885CCNH 1845/4885CCNK 539/4885 |
| US-12351571-B2 | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases | FGFR3, FGFR4, FGFR1 | CDK7 96/4885CCNH 1334/4885CCNK 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.